The typical candidate in brief

Cartilage damage that has not responded to physiotherapy, activity modification, or standard pain management often brings patients to a crossroads. ChondroFiller injection — an ultrasound-guided outpatient procedure — sits at that crossroads as an option worth formal assessment for a wide range of adults.

The treatment is an acellular collagen scaffold placed into the joint under image guidance. Once in situ, it gels within minutes, creating a matrix that recruits the patient's own progenitor cells through a process called acellular matrix-induced chondrogenesis. No surgical incision or theatre admission is involved.

Candidates span a broad clinical picture: both diffuse joint wear — including Kellgren-Lawrence Grade III/IV osteoarthritis — and focal cartilage lesions fall within the scope of assessment. There is no published upper age limit; individual regenerative capacity is evaluated at consultation rather than ruled out by age alone. Even bone-on-bone appearances on imaging represent one clinical finding among several that a specialist will weigh, rather than a blanket disqualifier for the injection pathway.

The gateway is consistent across all presentations: cartilage damage confirmed on MRI or X-ray, combined with conservative care that has not delivered adequate relief.

Conditions that commonly lead to an assessment

Several distinct underlying conditions may prompt a referral or self-referral for specialist assessment, and recognising which category fits your situation is a useful first step.

Degenerative

Osteoarthritis at any Kellgren-Lawrence grade may lead to an assessment; grades III and IV — where cartilage loss is substantial or bone contact has occurred — are the profile most commonly associated with the injection pathway specifically.

Post-traumatic and sports-related

Acute or cumulative cartilage injuries following a sporting accident, ligament rupture, or direct joint trauma are a frequent referral trigger. These lesions are often focal and may present in younger, otherwise active patients.

Developmental and structural

Osteochondritis dissecans (OCD), in which a segment of cartilage and underlying bone partially or fully detaches, is a recognised indication. Femoroacetabular impingement (FAI), where abnormal bony contact damages the hip cartilage over time, may also lead to assessment where imaging confirms the cartilage loss.

Overuse and inflammatory

Chronic overuse syndromes — particularly in load-bearing joints — and ongoing inflammatory joint conditions with documented cartilage involvement fall within the scope of evaluation.

Knee, hip, and ankle are the joints most commonly assessed, though shoulder, elbow, wrist, foot, and hand may be relevant for focal sports-related or post-traumatic defects. In all cases, imaging confirmation of cartilage damage is required before a treatment pathway is discussed.

Defect characteristics that matter most

The imaging report is where candidacy becomes most concrete. When an MRI describes Grade III or Grade IV cartilage damage, it means cartilage has been worn away to a clinically significant depth — Grade III indicates loss extending more than halfway through the cartilage layer, whilst Grade IV means full-thickness loss that reaches the underlying bone. Both grades fall within the scope of ChondroFiller assessment.

Two features of the defect then shape which approach a specialist is likely to recommend. First, whether the damage is focal — a discrete, contained lesion with reasonably healthy cartilage at its edges — or diffuse, spread across a broader area of the joint surface. Focal, contained defects with intact perilesional cartilage represent the most clearly defined target, and unstable or isolated localised lesions within that category are considered particularly suitable for evaluation.

Second, the injection pathway does not impose a defect-size ceiling. Some established cartilage interventions are designed for lesions under two to four centimetres squared, so the absence of a fixed size limit is a meaningful practical distinction — though it does not mean every presentation is equally straightforward to treat.

At consultation, the specialist will also review the condition of the surrounding cartilage and the subchondral bone (the bony layer immediately beneath the cartilage), since both influence how well the scaffold can support the body's own repair processes.

How candidacy is confirmed: MRI, conservative-treatment history, and clinical review

Three questions tend to structure a ChondroFiller pre-treatment consultation: what does the imaging show, what has already been tried, and what is the patient's likely capacity to respond?

MRI answers the first of these in the most clinically useful way. The scan characterises the lesion's pattern — focal versus diffuse, contained versus indistinct borders — and guides the specialist in determining which pathway, if either, is appropriate. An X-ray can confirm joint-space narrowing, but MRI reveals the depth, distribution, and condition of surrounding cartilage that a plain film cannot, and that detail directly shapes the treatment plan.

Conservative treatment history forms a genuine clinical gate, not an administrative formality. Physiotherapy, activity modification, and standard oral analgesia are expected to have been tried and found insufficient before specialist assessment is warranted. Bringing a record of what has been attempted, and for how long, makes this part of the consultation considerably more efficient.

The third element — individual regenerative capacity — is the most contextual. No single factor such as age or BMI automatically disqualifies a patient; the clinician weighs the overall picture of joint health, symptom duration, previous injections or procedures, and general health status at the time of consultation. Candidacy is therefore determined through a rounded clinical review rather than a fixed checklist.

Taken together, these three areas make the assessment more structured than a corticosteroid or viscosupplementation consultation, which does not require equivalent imaging review or treatment-history gating — a difference that reflects the regenerative intent of the treatment rather than bureaucratic complexity.

What the evidence shows for well-selected patients

In clinical evaluations of well-selected knee patients, IKDC functional scores improved by approximately 30 points on average. The Jerosch et al. post-market clinical follow-up study recorded a mean improvement of 32.4 points, with patients reaching an IKDC score of around 80 at three-year follow-up — a level generally associated with good functional joint performance. Structural imaging corroborated these functional results: MOCART scores of 81.6 to 84.3 in European knee studies indicate greater than 80% defect filling and satisfactory integration of repair tissue with native cartilage.

For the hip, published data show a Harris Hip Score improvement of approximately 33 points in patients with focal damage and femoroacetabular impingement — a comparable magnitude of functional gain to that seen in knee cohorts.

Across more than 19,000 cases performed globally, the reported complication rate has been close to zero, and reoperation has been required in approximately 3–8% of treated patients. By comparison, reoperation rates for microfracture have been reported at up to 41% in published series — though this represents a different patient population and procedure type, not a direct head-to-head comparison.

Two evidence limitations are worth naming clearly. No published randomised controlled trial has compared outcomes between matched patient groups receiving ChondroFiller and a control intervention. For the injection pathway specifically, follow-up data beyond three years remain limited in the available literature. Neither gap invalidates the case for individual specialist assessment, but both are relevant when weighing expectations against the published evidence base.

Getting assessed and finding the right specialist

Confirming candidacy requires a consultation with an MSK specialist experienced in cartilage injection therapies — self-assessment from imaging reports alone is not sufficient, and patients who are unsure about their eligibility should not rule themselves out before speaking to a clinician.

To make that consultation as productive as possible, it helps to arrive with any existing MRI reports, a GP referral or summary letter, and a clear account of which treatments have already been tried and for how long. If no MRI has yet been arranged, a specialist can advise on the appropriate imaging sequence before or at the point of assessment.

Availability of ChondroFiller injection varies across the UK by region and clinical setting. The Search MSK specialist directory — a UK-wide listing of MSK clinicians searchable by region and specialty — includes practitioners who offer ChondroFiller and related cartilage treatments; the filters make it straightforward to identify a suitably experienced clinician nearby.

A well-structured consultation should resolve the central question directly: whether the injection pathway fits the clinical picture and, if so, what the realistic next steps involve.